Ceryvyn — Translating unique science into breakthrough medicines

Translating unique science
into breakthrough medicines

Pioneering the first potentially disease-modifying therapy for LAM (lymphangioleiomyomatosis).

Welcome to Ceryvyn

Living with the rare disease LAM

About LAM

Combining Australian innovation with international scientific leadership to develop a differentiated therapy targeting the underlying biology of lymphangioleiomyomatosis (LAM).

New hope for patients

About Us

Experienced drug developers committed to innovation for LAM

About LAM

LAM is a progressive rare disease which primarily damages the lungs of women

Investor Hub

A range of
in-depth resources

About Us
We welcome patients at 2702 Memory Lane,
office 5, Chicago, IL 60605.

Investor Hub
Monday – Friday: 08.00 – 17.00
Saturday: 09.00 – 12.00

Our science

Our lead asset is CYV-101, a fusion protein proven to target the dysregulated biology resulting in LAM (lymphangioleiomyomatosis), a progressive disease that renders breathing difficult and shortens lifespan.

Ceryvyn is focused on rapid, efficient development of CYV-101, leveraging data from over 2,000 patients previously dosed with CYV-101 in late-stage development.

We are experienced drug developers with particular expertise in VEGF biology advancing towards a clearly defined goal: to help sufferers of the rare disease LAM.

We are a proud product of Australian science and Australian investment and we have built a lean team to advance CYV-101 in a disciplined way through clinical development.

About us